ADI 004
Alternative Names: ADI-004Latest Information Update: 22 Apr 2022
At a glance
- Originator Adicet Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 22 Apr 2022 Adicet Bio has intellectual property rights for platforms
- 20 Apr 2022 Early research in Haematological malignancies in USA (Parenteral), prior to April 2022 (Adicet Bio pipeline, April 2022)
- 20 Apr 2022 Early research in Solid tumours in USA (Parenteral), prior to April 2022 (Adicet Bio pipeline, April 2022)